which included 407 adults with obesity and moderate knee osteoarthritis. Patients had an average baseline weight of 239.5 pounds and were either given a 2.4-mg weekly dose of semaglutide in the form ...
Immunis, Inc., a clinical-stage biotech developing novel, multi-active biologics for age and disease-related immune dysregulation, is proud to announce the successful completion of its Phase 1/2a ...